Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barrier integrity, and regulate immune response to prevent...
3 insider purchases on record · latest filing 2022-07-07.
Insiders have also filed 167 sale transactions at MCRB.